紫杉醇联合腹腔热灌注顺铂治疗胃癌合并腹水的近期临疗效及安全性分析

目的:分析紫杉醇联合腹腔热灌注顺铂治疗胃癌合并腹水病人的近期临床疗效和安全性。方法:收集胃癌合并腹水病人75例，按照病人治疗方式的不同分为2组。对照组采用紫杉醇静脉滴注联合腹腔直接灌注顺铂方案，观察组采用紫杉醇静脉滴注联合腹腔恒温循环热灌注顺铂方案治疗。比较2组病人临床疗效、血清癌胚抗原（CEA）水平、生存质量、1年累积生存率及不良反应发生率。结果:观察组总有效率为60.00%，高于对照组的37.14%（P<0.05）；观察组病人血清CEA下降水平较对照组更明显（P<0.01）；观察组治疗后生存质量优于对照组（P<0.05）；观察组不良反应恶心呕吐程度明显低于对照组（P<0.01），其他不良反应症状程度在2组间差异均无统计学意义（P>0.05）；2组1年累积生存率差异无统计学意义（P>0.05）。结论:紫杉醇静脉滴注联合腹腔热灌注顺铂治疗胃癌合并腹水近期临床治疗效果较好，可改善部分病人生存质量，并可能延长部分病人生存时间不良反应可耐受。

The short-term clinical efficacy and safety of paclitaxel combined with cisplatin byhyperthermic intraperitoneal perfusion in the treatment of gastric cancer complicated with ascites

Objective:To investigate the clinical efficacy and safety of paclitaxel combined with hyperthermic intraperitoneal infusion of cisplatin in the treatment of gastric cancer patients with ascites.Methods:Seventy-five gastric cancer patients with ascites were divided into the observation group and control group according to the different treatment methods.The observation group was treated with intravenous infusion of paclitaxel combined with hyperthermic intraperitoneal perfusion circulation cisplatin,and the control group was treated with intravenous infusion of paclitaxel combined with direct abdominal infusion of cisplatin.The clinical effects,level of serum carcinoembryonic antigen(CEA),quality of life,1-year cumulative survival rate and incidence rate of adverse reaction between two groups were compared.Results:The total effective rates of observation group and control group were 60.00% and 37.14%,respectively,and the difference of which was statistically significant(P<0.05).The decreasing degree of serum CEA level in observation group was more significant compared with control group(P<0.01).The survival quality in observation group was better than that in control group after treatment(P<0.05).The degree of adverse reactions(nausea and vomiting) in observation group was lighter than that in control group(P<0.01),and the difference of other adverse reactions between two groups was not statistically significant(P>0.05).The difference of 1-year cumulative survival rate between two groups was not statistically significant(P>0.05).Conclusions:The short-term clinical efficacy of paclitaxel combined with hyperthermic intraperitoneal infusion of cisplatin in the treatment of gastric cancer patients with ascites is good,which can improve the survival quality of patients,and prolong the survival time of part of patients.The adverse reaction can be tolerated by patients.